1
|
Aly NI, Elnaker YF, Salama ZTS, Diab MS, Saber EA, Sotohy SA, Elfeil WK, Khodeir MH. Preparation and the assessed efficacy of oral baits for the vaccination of free-roaming dogs against rabies. Vet World 2022; 15:1383-1390. [PMID: 35765489 PMCID: PMC9210852 DOI: 10.14202/vetworld.2022.1383-1390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Accepted: 04/07/2022] [Indexed: 11/30/2022] Open
Abstract
Background and Aim: Rabies is considered a highly fatal zoonotic disease and many deaths in humans have been associated with dog bites. This study was designed to prepare an oral anti-rabies vaccine in the form of baits to eliminate the disease in free-roaming dogs and subsequently protect humans from dog bites. Materials and Methods: The Evelyn Rokintniki Abelseth (ERA) rabies virus strain was propagated in baby hamster kidney cell cultures and adjusted to the recommended dose for application. Four forms of oral baits were employed with the rabies vaccine, which was evaluated for safety, acceptability, and potency in different dog groups. Enzyme-Linked Immunosorbent Assay (ELISA) and the serum neutralization test (SNT) were used to determine the protective rabies antibody titer in the sera of vaccinated dogs. Results: According to the results, a dose of 3 mL of the ERA strain, containing a viral titer of 107.6 TCID50/mL, induced a mean antibody titer of 25.6 by SNT, and the PI% was 75.7 by Block ELISA, providing a protective level of the rabies antibody in 100% of vaccinated dogs. All used baits were found to be safe, inducing no abnormal general post-vaccination signs (the signs are limited to mild fever, mild loss of appetite, and mild-to-moderate loss of energy for 24-36 h after vaccination). Conclusion: It was found that most of the accepted and highly potent bait types consisted of a mixture of wheat flour, vegetable oil, sodium alginate, corn starch, meat meal, cellulose gum, and water. This dog meal was covered with bran and edible wax to seal the bait cavity after inserting the vaccine sachet. This bait was able to induce a protective level of rabies antibodies in 100% of vaccinated dogs after receiving one bait/dog. Hence, such a bait could be recommended for use in the protection of free-roaming dogs and the elimination of the disease.
Collapse
Affiliation(s)
- Naglaa I. Aly
- Department of Pet Animal Vaccine Research Veterinary Serum and Vaccine Research Institute, Agriculture Research Center, Ministry of Agriculture, Abassia, Cairo, Egypt
| | - Yasser F. Elnaker
- Department of Infectious Diseases, Faculty of Veterinary Medicine, New Valley University, El-Kharga, Egypt
| | - Zeinab T. S. Salama
- Department of Pet Animal Vaccine Research Veterinary Serum and Vaccine Research Institute, Agriculture Research Center, Ministry of Agriculture, Abassia, Cairo, Egypt
| | - Mohamed S. Diab
- Department of Animal Hygiene and Zoonoses, Faculty of Veterinary Medicine, New Valley University, El-Kharga, Egypt
| | - Eman A. Saber
- Department of Infectious Diseases, Faculty of Veterinary Medicine, New Valley University, El-Kharga, Egypt
| | - Sotohy A. Sotohy
- Department of Animal, Poultry and Environmental Hygiene, Faculty of Veterinary Medicine, Assiut University, Asyut, Egypt
| | - Wael K. Elfeil
- Department of Avian and Rabbit, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt
| | - Mohamed H. Khodeir
- Department of Pet Animal Vaccine Research Veterinary Serum and Vaccine Research Institute, Agriculture Research Center, Ministry of Agriculture, Abassia, Cairo, Egypt
| |
Collapse
|
2
|
Kamel M, El-Sayed A. Utilization of herpesviridae as recombinant viral vectors in vaccine development against animal pathogens. Virus Res 2019; 270:197648. [PMID: 31279828 DOI: 10.1016/j.virusres.2019.197648] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2019] [Revised: 06/27/2019] [Accepted: 06/28/2019] [Indexed: 02/06/2023]
Abstract
Throughout the past few decades, numerous viral species have been generated as vaccine vectors. Every viral vector has its own distinct characteristics. For example, the family herpesviridae encompasses several viruses that have medical and veterinary importance. Attenuated herpesviruses are developed as vectors to convey heterologous immunogens targeting several serious and crucial pathogens. Some of these vectors have already been licensed for use in the veterinary field. One of their prominent features is their capability to accommodate large amount of foreign DNA, and to stimulate both cell-mediated and humoral immune responses. A better understanding of vector-host interaction builds up a robust foundation for the future development of herpesviruses-based vectors. At the time, many molecular tools are applied to enable the generation of herpesvirus-based recombinant vaccine vectors such as BAC technology, homologous and two-step en passant mutagenesis, codon optimization, and the CRISPR/Cas9 system. This review article highlights the most important techniques applied in constructing recombinant herpesviruses vectors, advantages and disadvantages of each recombinant herpesvirus vector, and the most recent research regarding their use to control major animal diseases.
Collapse
Affiliation(s)
- Mohamed Kamel
- Faculty of Veterinary Medicine, Department of Medicine and Infectious Diseases, Cairo University, Giza, Egypt.
| | - Amr El-Sayed
- Faculty of Veterinary Medicine, Department of Medicine and Infectious Diseases, Cairo University, Giza, Egypt
| |
Collapse
|
3
|
Rabies vaccine development by expression of recombinant viral glycoprotein. Arch Virol 2016; 162:323-332. [PMID: 27796547 DOI: 10.1007/s00705-016-3128-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2016] [Accepted: 10/24/2016] [Indexed: 10/20/2022]
Abstract
The rabies virus envelope glycoprotein (RVGP) is the main antigen of rabies virus and is the only viral component present in all new rabies vaccines being proposed. Many approaches have been taken since DNA recombinant technology became available to express an immunogenic recombinant rabies virus glycoprotein (rRVGP). These attempts are reviewed here, and the relevant results are discussed with respect to the general characteristics of the rRVGP, the expression system used, the expression levels achieved, the similarity of the rRVGP to the native glycoprotein, and the immunogenicity of the vaccine preparation. The most recent studies of rabies vaccine development have concentrated on in vivo expression of rRVGP by viral vector transduction, serving as the biotechnological basis for a new generation of rabies vaccines.
Collapse
|
4
|
Vos A, Conzelmann KK, Finke S, Müller T, Teifke J, Fooks AR, Neubert A. Immunogenicity studies in carnivores using a rabies virus construct with a site-directed deletion in the phosphoprotein. Adv Prev Med 2011; 2011:898171. [PMID: 21991446 PMCID: PMC3177460 DOI: 10.4061/2011/898171] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2011] [Revised: 05/03/2011] [Accepted: 06/29/2011] [Indexed: 12/17/2022] Open
Abstract
Different approaches have been applied to develop highly attenuated rabies virus vaccines for oral vaccination of mesocarnivores. One prototype vaccine construct is SAD dIND1, which contains a deletion in the P-gene severely limiting the inhibition of type-1 interferon induction. Immunogenicity studies in foxes and skunks were undertaken to investigate whether this highly attenuated vaccine would be more immunogenic than the parental SAD B19 vaccine strain. In foxes, it was demonstrated that SAD dIND1 protected the animals against a rabies infection after a single oral dose, although virus neutralizing antibody titres were lower than in foxes orally vaccinated with the SAD B19 virus as observed in previous experiments. In contrast, skunks receiving 10(7.5) FFU SAD dIND1 did not develop virus neutralizing antibodies and were not protected against a subsequent rabies infection.
Collapse
Affiliation(s)
- Ad Vos
- IDT Biologika GmbH, Am Pharmapark, 06855 Dessau-Rosslau, Germany
| | | | | | | | | | | | | |
Collapse
|
5
|
Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems. Vaccine 2009; 26:6508-28. [PMID: 18838097 PMCID: PMC7131726 DOI: 10.1016/j.vaccine.2008.09.044] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2008] [Revised: 08/21/2008] [Accepted: 09/16/2008] [Indexed: 11/30/2022]
Abstract
The recent advances in molecular genetics, pathogenesis and immunology have provided an optimal framework for developing novel approaches in the rational design of vaccines effective against viral epizootic diseases. This paper reviews most of the viral-vector based antigen delivery systems (ADSs) recently developed for vaccine testing in veterinary species, including attenuated virus and DNA and RNA viral vectors. Besides their usefulness in vaccinology, these ADSs constitute invaluable tools to researchers for understanding the nature of protective responses in different species, opening the possibility of modulating or potentiating relevant immune mechanisms involved in protection.
Collapse
|
6
|
Yoneda A, Tuchiya K, Takashima Y, Arakawa T, Tsuji N, Hayashi Y, Matsumoto Y. Protection of mice from rabies by intranasal immunization with inactivated rabies virus. Exp Anim 2008; 57:1-9. [PMID: 18256513 DOI: 10.1538/expanim.57.1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
The mucosal immunization method is a needle-free alternative way of vaccination. This study evaluated the efficacy of mucosal immunization for rabies. Mice were intranasally administered five times with inactivated and concentrated rabies virus antigen (CRV) supplemented with or without cholera toxin (CT). The anti-rabies virus antibody titer of mice intranasally immunized with CRV plus CT (CRV/CT) was comparable to that of mice intraperitoneally immunized twice with the same amount of CRV. Virus neutralizing (VNA) titers of mice immunized intranasally with CRV/CT were slightly lower than those of intraperitoneally immunized mice. Both anti-rabies virus ELISA antibody and VNA titers of mice immunized with CRV without CT were significantly lower than those of mice immunized with CRV/CT. In mice intranasally immunized with CRV/CT, and intraperitoneally immunized mice, high levels of IgG(2a) antibody were detected, suggesting the activation of Th1-driven cellular immunity by the two ways of immunization. All immunized mice were challenged intracerebrally with a lethal dose of virulent rabies virus CVS strain. The survival rates of mice immunized with CRV/CT and CRV without CT were 67% and 17%, respectively, while the rate of intraperitoneally immunized mice was 100%. Antigen-specific whole IgG and IgG(2a), and VNA titers of survived mice were significantly higher than those of dead mice at the challenge day. These data suggest the possibility of intranasal immunization with inactivated antigen as a rabies vaccination strategy and the importance of a mucosal adjuvant such as CT.
Collapse
Affiliation(s)
- Atsushi Yoneda
- Department of Global Animal Resource Science, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
7
|
Strive T, Hardy CM, Wright J, Reubel GH. A virus vector based on Canine Herpesvirus for vaccine applications in canids. Vet Microbiol 2007; 119:173-83. [PMID: 17079096 DOI: 10.1016/j.vetmic.2006.09.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2006] [Revised: 09/15/2006] [Accepted: 09/20/2006] [Indexed: 11/22/2022]
Abstract
Canine Herpesvirus (CHV) is being developed as a virus vector for the vaccination of European red foxes. However, initial studies using recombinant CHV vaccines in foxes revealed viral attenuation and lack of antibody response to inserted foreign antigens. These findings were attributed both to inactivation of the thymidine kinase (TK) gene and excess foreign genetic material in the recombinant viral genome. In this study, we report an improved CHV-bacterial artificial chromosome (BAC) vector system designed to overcome attenuation in foxes. A non-essential region was identified in the CHV genome as an alternative insertion site for foreign genes. Replacement of a guanine/cytosine (GC)-rich intergenic region between UL21 and UL22 of CHV with a marker gene did not change growth behaviour in vitro, showing that this region is not essential for virus growth in cell culture. We subsequently produced a CHV-BAC vector with an intact TK gene in which the bacterial genes and the antigen expression cassette were inserted into this GC-rich locus. Unlike earlier constructs, the new CHV-BAC allowed self-excision of the bacterial genes via homologous recombination after transfection of BACs into cell culture. The BAC-CHV system was used to produce a recombinant virus that constitutively expressed porcine zona pellucida subunit C protein between the UL21 and UL22 genes of CHV. Complete self-excision of the bacterial genes from CHV was achieved within one round of replication whilst retaining antigen gene expression.
Collapse
Affiliation(s)
- T Strive
- Commonwealth Scientific and Industrial Research Organisation, GPO Box 1700, Canberra, ACT 2601, Australia.
| | | | | | | |
Collapse
|
8
|
Strive T, Hardy CM, Reubel GH. Prospects for immunocontraception in the European red fox (Vulpes vulpes). WILDLIFE RESEARCH 2007. [DOI: 10.1071/wr07007] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The European red fox is an introduced pest species in Australia for which improved means of control are urgently needed. Research efforts have focussed recently on the development of novel biological control methods to reduce the serious impact this species continues to have on both native fauna and the sheep industry. The ultimate goal has been to generate an antifertility vaccine for use on foxes that relies on a process termed ‘immunocontraception’. A variety of proteins derived from sperm and oocytes, together with different delivery vectors, have been experimentally assessed for their ability to induce immunocontraceptive responses in foxes. Vaccine vectors screened have included Salmonella typhimurium, vaccinia virus and canine herpesvirus but suppression of fertility has yet to be achieved with any combination of antigen and delivery vector. Downregulation of fox mucosal antibodies during oestrus, lack of vector replication and low antibody responses to the target antigens have been the main constraints in successful fertility control. The fox is not well known as an experimental animal and the logistics of dealing with this difficult-to-handle species proved to be a major challenge when compared with other species, such as rabbits and mice. Despite these difficulties, research on fox immunocontraception has generated important insights into the reproductive biology, husbandry, biology and basic immunology of viral vectors in European red foxes. This information represents a valuable knowledge base should antifertility vaccination for foxes be revisited in the future.
Collapse
|
9
|
Strive T, Hardy CM, French N, Wright JD, Nagaraja N, Reubel GH. Development of canine herpesvirus based antifertility vaccines for foxes using bacterial artificial chromosomes. Vaccine 2006; 24:980-8. [PMID: 16198458 DOI: 10.1016/j.vaccine.2005.08.078] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2005] [Revised: 07/13/2005] [Accepted: 08/07/2005] [Indexed: 11/29/2022]
Abstract
Using bacterial artificial chromosome (BAC) technology, a canine herpesvirus (CHV)-based recombinant vaccine vector was produced for the development of an antifertility vaccine for foxes. Infectious viruses were recovered following transfection of canid cells with a BAC plasmid carrying the complete CHV genome. In vitro growth characteristics of BAC-derived viruses were similar to that of wildtype (wt)-CHV. Two recombinant antigens, fox zona pellucida protein subunit 3 (fZPC) and enhanced green fluorescent protein (EGFP) as control antigen, were inserted into thymidine kinase (TK) locus of the CHV genome and shown to be efficiently expressed in vitro. Inoculation of foxes with transgenic CHVs induced CHV specific antibodies, but was innocuous and failed to elicit transgene-specific antibody responses. Infectious virus or viral DNA was not detected in mucosal secretions or tissues of vaccinated foxes. The CHV-BAC system proved to be a quick and reliable method to manipulate the CHV genome. It will help to readily apply changes in the vector design in order to improve virus replication in vivo.
Collapse
Affiliation(s)
- Tanja Strive
- Pest Animal Control Cooperative Research Centre CSIRO Sustainable Ecosystems, Canberra, ACT, Australia.
| | | | | | | | | | | |
Collapse
|
10
|
Arii J, Hushur O, Kato K, Kawaguchi Y, Tohya Y, Akashi H. Construction of an infectious clone of canine herpesvirus genome as a bacterial artificial chromosome. Microbes Infect 2006; 8:1054-63. [PMID: 16515874 DOI: 10.1016/j.micinf.2005.11.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2005] [Revised: 10/31/2005] [Accepted: 10/31/2005] [Indexed: 10/25/2022]
Abstract
Canine herpesvirus (CHV) is an attractive candidate not only for use as a recombinant vaccine to protect dogs from a variety of canine pathogens but also as a viral vector for gene therapy in domestic animals. However, developments in this area have been impeded by the complicated techniques used for eukaryotic homologous recombination. To overcome these problems, we used bacterial artificial chromosomes (BACs) to generate infectious BACs. Our findings may be summarized as follows: (i) the CHV genome (pCHV/BAC), in which a BAC flanked by loxP sites was inserted into the thymidine kinase gene, was maintained in Escherichia coli; (ii) transfection of pCHV/BAC into A-72 cells resulted in the production of infectious virus; (iii) the BAC vector sequence was almost perfectly excisable from the genome of the reconstituted virus CHV/BAC by co-infection with CHV/BAC and a recombinant adenovirus that expressed the Cre recombinase; and (iv) a recombinant virus in which the glycoprotein C gene was deleted was generated by lambda recombination followed by Flp recombination, which resulted in a reduction in viral titer compared with that of the wild-type virus. The infectious clone pCHV/BAC is useful for the modification of the CHV genome using bacterial genetics, and CHV/BAC should have multiple applications in the rapid generation of genetically engineered CHV recombinants and the development of CHV vectors for vaccination and gene therapy in domestic animals.
Collapse
Affiliation(s)
- Jun Arii
- Department of Veterinary Microbiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | | | | | | | | | | |
Collapse
|
11
|
Reubel GH, Wright J, Pekin J, French N, Strive T. Suitability of canine herpesvirus as a vector for oral bait vaccination of foxes. Vet Microbiol 2006; 114:225-39. [PMID: 16417978 PMCID: PMC7126022 DOI: 10.1016/j.vetmic.2005.12.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2005] [Revised: 12/09/2005] [Accepted: 12/13/2005] [Indexed: 01/19/2023]
Abstract
Studies were conducted to evaluate the feasibility of using canine herpesvirus (CHV) as a vaccine vector for bait-delivered oral vaccination of wild foxes. To test the viability of CHV in baits, CHV was freeze-dried, incorporated into different baits, stored, and the remaining viral infectivity tested in cell culture after varying periods of time at different storage temperatures. Experimental baits (mouse carcasses) and commercial baits (FOXOFF and PROBAIT) were prepared with either liquid or freeze-dried CHV and tested in two fox trials for their capacity to induce CHV-specific antibodies following oral baiting. Freeze-drying and storage temperatures below 0 °C had a stabilizing effect to virus infectivity. When stored at −20 °C, freeze-dried CHV retained its full infectivity for up to 3 months in PROBAIT baits, the remaining infectivity in FOXOFF baits was 100-fold less. Oral baiting with CHV induced antiviral serum antibodies in all vaccinated foxes (20/20). None of the vaccinated foxes became ill or shed infectious virus into the environment although viral DNA was detected in body secretions as evaluated by PCR. The results indicate that CHV can be freeze-dried and stored over extended periods of time without loosing much of its infectivity. This is the first report of CHV being used for oral bait vaccination of foxes. It appears that CHV is well suited for use as a recombinant vector for wild canids.
Collapse
Affiliation(s)
| | | | | | | | - Tanja Strive
- Corresponding author. Tel.: +61 2 6246 4155; fax: +61 2 6246 4177.
| |
Collapse
|
12
|
Qiu HJ, Tian ZJ, Tong GZ, Zhou YJ, Ni JQ, Luo YZ, Cai XH. Protective immunity induced by a recombinant pseudorabies virus expressing the GP5 of porcine reproductive and respiratory syndrome virus in piglets. Vet Immunol Immunopathol 2005; 106:309-19. [PMID: 15963827 DOI: 10.1016/j.vetimm.2005.03.008] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2004] [Revised: 03/01/2005] [Accepted: 03/21/2005] [Indexed: 12/21/2022]
Abstract
Pseudorabies virus (PRV) has been developed as a vaccine vector for expressing foreign immunogens. Porcine reproductive and respiratory syndrome (PRRS), caused by porcine reproductive and respiratory syndrome virus (PRRSV), continues to be a major problem to the pork industry worldwide. Many vaccine strategies have been developed to control the disease but most of them turn out to be unsuccessful. The objective of this research was to explore the feasibility of PRV-based vector vaccine in protection against PRRSV. A live attenuated vaccine-based PRV recombinant expressing the envelope protein GP5 of PRRSV was generated using recombinant DNA techniques. The Bartha-K61-derived recombinant virus, named rPRV-GP5, was shown to express PRRSV GP5 efficiently. Sixteen healthy piglets were assigned to one of four groups (one to four, four pigs per group). Animals in Groups 1 and 2 were each inoculated intramuscularly and intranasally with 10(7.0) PFU of rPRV-GP5 and its parent Bartha-K61, respectively; Group 3 were vaccinated intramuscularly with one-dose of PRRS inactivated vaccine; Group 4 was served as non-vaccinated control. One month later, all animals were all challenged with 10(6.5) TCID(50) of virulent PRRSV CH-1a. All animals in Groups 1 and 3 remained clinically healthy before and after challenge, with only a short period of fever (no more than 41 degrees C and 3 days), mild and gradually improving lung and kidney lesions, and short-term viremia (2 and 3 week, respectively) in spite of no detectable anti-PRRSV antibody before challenge. On the other hand, all animals in the other two groups showed evident clinical signs with higher temperatures (more than 41 degrees C) after challenge, and severe lung, kidney and spleen lesions and extended viremia (4 weeks). The results indicate that the rPRV-GP5 is safe for vaccinates and able to confer significant protection against clinical disease and reduce pathogenic lesions induced by PRRSV challenge in vaccinated pigs.
Collapse
Affiliation(s)
- Hua-Ji Qiu
- National Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, No. 427 Maduan Street, Harbin 150001, PR China
| | | | | | | | | | | | | |
Collapse
|
13
|
Rizvanov AA, van Geelen AGM, Morzunov S, Otteson EW, Bohlman C, Pari GS, St Jeor SC. Generation of a recombinant cytomegalovirus for expression of a hantavirus glycoprotein. J Virol 2003; 77:12203-10. [PMID: 14581557 PMCID: PMC254267 DOI: 10.1128/jvi.77.22.12203-12210.2003] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2003] [Accepted: 07/29/2003] [Indexed: 11/20/2022] Open
Abstract
A cytomegalovirus (CMV) was isolated from its natural host, Peromyscus maniculatus, and was designated Peromyscus CMV (PCMV). A recombinant PCMV was constructed that contained Sin Nombre virus glycoprotein G1 (SNV-G1) fused in frame to the enhanced green fluorescent protein (EGFP) gene inserted into a site homologous to the human CMV UL33 (P33) gene. The recombinant CMV was used for expression and immunization of deer mice against SNV-G1. The results of the study indicate that P. maniculatus could be infected with as few as 10 virus particles of recombinant virus. Challenge of P. maniculatus with either recombinant or wild-type PCMV produced no overt pathology in infected animals. P. maniculatus immunized with recombinant virus developed an antibody response to SNV and EGFP. When rechallenged with recombinant virus, animals exhibited an anamnestic response against SNV. Interestingly, a preexisting immune response against PCMV did not prevent reinfection with recombinant PCMV.
Collapse
Affiliation(s)
- Albert A Rizvanov
- Department of Microbiology, University of Nevada at Reno, Reno, Nevada 89557, USA
| | | | | | | | | | | | | |
Collapse
|
14
|
Reubel GH, Pekin J, Webb-Wagg K, Hardy CM. Nucleotide sequence of glycoprotein genes B, C, D, G, H and I, the thymidine kinase and protein kinase genes and gene homologue UL24 of an Australian isolate of canine herpesvirus. Virus Genes 2002; 25:195-200. [PMID: 12416682 DOI: 10.1023/a:1020118003743] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
We report the complete nucleotide (nt) sequence of nine genes of an Australian isolate of canine herpesvirus (CHV). Four of them are located in the unique short (US) region: glycoprotein (g) genes gG, gD and gI, and the protein kinase gene. Five are in the unique long (UL) region: the thymidine kinase gene, gB, gC, gH, and gene homologue UL24. Partial sequence was determined for four genes, two in the UL region (UL21 and virion protein) and two in the US region (US2 and gE). A repeat sequence of 382 nt with unknown function was identified in the 615 nt intergenic region between gH and UL21. A total of 16.93 kb was sequenced and compared with sequences from CHV isolates from the USA, France, Japan and Australia. Only minor nt and/or amino acid (aa) differences were observed.
Collapse
Affiliation(s)
- Gerhard Herbert Reubel
- Pest Animal Control Cooperative Research Centre, CSIRO Sustainable Ecosystems, Canberra, Australia.
| | | | | | | |
Collapse
|
15
|
Nishikawa Y, Kimura M, Xuan X, Makala L, Nagasawa H, Mikami T, Otsuka H. Canine herpesvirus ORF2 is a membrane protein modified by N-linked glycosylation. Virus Res 2002; 87:1-9. [PMID: 12135784 DOI: 10.1016/s0168-1702(01)00424-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Canine herpesvirus (CHV) ORF2, located downstream of the glycoprotein C (gC) gene, has homologues with some of the alphaherpesviruses. To characterize CHV OFR2, a recombinant CHV carrying a LacZ gene in the ORF2 locus, and recombinant vaccinia virus expressing ORF2 protein were constructed. Northern blot analysis revealed ORF2 and a gamma2 class late gene, and its protein product was detectable in CHV-infected cells reacted with ORF2 protein antiserum. Tunicamycin and N-glycosidase F treatment revealed that the ORF2 protein was modified by N-linked glycosylation. Fractionation and immune fluorescence analyses of the CHV-infected cells showed the ORF2 as a membrane protein transportable to the surface of infected cells. In vitro, the ORF2 protein did not affect viral replication and cell-to-cell viral spreading. Present findings represent the first evidence pointing to the CHV ORF2 as a membrane protein modified by an N-linked glycosylation.
Collapse
Affiliation(s)
- Yoshifumi Nishikawa
- Department of Global Agricultural Science, Graduate School of Agricultural and Life Science, The University of Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
16
|
Nishikawa Y, Ikeda H, Fukumoto S, Xuan X, Nagasawa H, Otsuka H, Mikami T. Immunization of dogs with a canine herpesvirus vector expressing Neospora caninum surface protein, NcSRS2. Int J Parasitol 2000; 30:1167-71. [PMID: 11027782 DOI: 10.1016/s0020-7519(00)00111-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
In order to develop a vaccine against Neospora caninum in dogs, we constructed recombinant canine herpesvirus (CHV) expressing N. caninum surface protein, NcSRS2. Indirect immunofluorescence indicated that the antigenic structure of the recombinant NcSRS2 was similar to the authentic parasite protein. The dogs immunised with recombinant virus produced IgG antibody to N. caninum, and their sera recognised the parasite protein on Western blot. The dogs inoculated with recombinant virus showed no clinical symptoms and infectious CHV was not recovered from the dogs, suggesting that recombinant CHV expressing N. caninum proteins may lead to a vaccine against neosporosis in dogs.
Collapse
MESH Headings
- Animals
- Antibodies, Protozoan/blood
- Antigens, Protozoan/analysis
- Antigens, Protozoan/immunology
- Antigens, Surface/immunology
- Blotting, Western/veterinary
- Coccidiosis/immunology
- Coccidiosis/prevention & control
- Coccidiosis/veterinary
- DNA Primers/chemistry
- Dog Diseases/immunology
- Dog Diseases/parasitology
- Dog Diseases/prevention & control
- Dogs
- Electrophoresis, Polyacrylamide Gel/veterinary
- Enzyme-Linked Immunosorbent Assay/veterinary
- Female
- Flow Cytometry/veterinary
- Fluorescent Antibody Technique, Indirect/veterinary
- Genetic Vectors/chemistry
- Herpesvirus 1, Canid/immunology
- Immunization/veterinary
- Male
- Neospora/chemistry
- Neospora/genetics
- Neospora/immunology
- Polymerase Chain Reaction/veterinary
- Protozoan Proteins/immunology
- Protozoan Vaccines/immunology
- Protozoan Vaccines/standards
- Vaccines, Synthetic/immunology
- Vaccines, Synthetic/standards
Collapse
Affiliation(s)
- Y Nishikawa
- The National Research Center for Protozoan Diseases, Obihiro University, Inada-cho, Obihiro, Hokkaido, 080-8555, Japan
| | | | | | | | | | | | | |
Collapse
|
17
|
Nakamichi K, Ohara K, Matsumoto Y, Otsuka H. Attachment and penetration of canine herpesvirus 1 in non-permissive cells. J Vet Med Sci 2000; 62:965-70. [PMID: 11039592 DOI: 10.1292/jvms.62.965] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Canine herpesvirus 1 (CHV-1) has a relatively narrow host cell range when compared to other alphaherpesviruses. The early events of CHV-1 infection in a permissive Madin-Darby canine kidney (MDCK) and non-permissive cell lines. In order to quantify attachment and penetration, were investigated quantitative competitive PCR (QCPCR) method was established for quantitation of CHV-1 DNA. In all non-permissive cells tested, no significant decrease in viral attachment was observed. When CHV-1 was treated with heparin, viral attachment to MDCK cells was reduced by 25% of the input CHV-1 attached to MDCK cells even in the presence of 50 microg/ml heparin. However, the attachment of CHV-1 to non-permissive cells was severely impaired by heparin treatment. In permissive MDCK cells, about 80% of attached CHV-1 penetrated into cells. However, only 4-10% of CHV-1 attached to non-permissive cells penetrated into cells. Our data indicated that CHV-1, like other herpesviruses, attached to permissive MDCK cells through two mechanisms: the first one is through the interaction mediated by heparan sulfate (HS) on the cell surface and the second involves unidentified viral component and the cellular receptor. In contrast, the non-permissive cells lacked the cellular receptor for the second attachment mechanism and the defect in viral penetration into non-permissive cell might be related to the lack of the cellular receptor.
Collapse
Affiliation(s)
- K Nakamichi
- Department of Global Animal Resource Science, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Japan
| | | | | | | |
Collapse
|
18
|
Nishikawa Y, Xuan X, Kimura M, Otsuka H. Characterization of pseudorabies virus glycoprotein B expressed by canine herpesvirus. J Vet Med Sci 1999; 61:1113-7. [PMID: 10563288 DOI: 10.1292/jvms.61.1113] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
A recombinant canine herpesvirus (CHV) which expressed glycoprotein B (gB) of pseudorabies virus (PrV) was constructed. The antigenicity of the PrV gB expressed by the recombinant CHV is similar to that of the native PrV. The expressed PrV gB was shown to be transported to the surface of infected cells as judged by an indirected immunofluorescence test. Antibodies raised in mice immunized with the recombinant CHV neutralized the infectivity of PrV in vitro. It is known that the authentic PrV gB exists as a glycoprotein complex, which consists of gBa, gBb and gBc. In MDCK cells, PrV gB expressed by the recombinant CHV was processed like authentic PrV gB, suggesting that the cleavage mechanism of PrV gB depends on a functional cleavage domain from PrV gB gene and protease from infected cells.
Collapse
Affiliation(s)
- Y Nishikawa
- Department of Global Agricultural Sciences, Graduate School of Agricultural and Life Science, University of Tokyo, Japan
| | | | | | | |
Collapse
|
19
|
Murata T, Xuan X, Otsuka H. Characterization of promoters integrated in the genome of bovine herpesvirus-1 (BHV-1). J Vet Med Sci 1999; 61:453-7. [PMID: 10379933 DOI: 10.1292/jvms.61.453] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Bovine herpesvirus-1 (BHV-1) has been used as a vector of live recombinant vaccines for cattle which express the genes of other pathogens. Because of the importance of the choice of the promoter which allows the efficient expression of the foreign genes in the BHV-1 vector, we compared the relative efficacy of various promoters integrated in the BHV-1 genome. The promoter sequences of the BHV-1 thymidine kinase (tk), gB, gC, SV40 early, and pseudorabies virus (PRV) immediate early (IE) genes were placed at the upstream of the open reading frame of the chloramphenycol acetyl transferase (CAT) gene and the promoter-CAT sequences were integrated into the tk gene of BHV-1 by homologous recombination. The promoter activity was assayed by measuring the CAT activity in the extracts of Madin Darby bovine kidney (MDBK) cells infected with the recombinant BHV-1. The PRV IE promoter was activated earlier and maintained at a higher level activity than the BHV-1 gB or gC promoters throughout the most of the growth phase of BHV-1. At the late phase, however, the activities of the BHV-1 gB and gC promoters reached the higher level. The BHV-1 tk promoter activity was low and the SV40 early promoter was hardly activated when integrated into the BHV-1 genome. promoter, recombinant BHV-1.
Collapse
Affiliation(s)
- T Murata
- Department of Global Agricultural Sciences, Graduate School of Agricultural and Life Science, The University of Tokyo, Japan
| | | | | |
Collapse
|